AZRX News and Press, AzurRx BioPharma Inc. From 07/08/19

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will have a management R&D update c...

Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency (EPI). Patients in study have persistent malnutrition and clinical symptoms of fat malabsorption despite bei...

Gainers:  Sotheby's (NYSE: BID ) +58% . Array BioPharma (NASDAQ: ARRY ) +57% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% . Vislink Technologies (NASDAQ: VISL ) +40% . MTech Acquisition (NASDAQ: MTEC ) +34% . Endurance International Group Holdings (NASDAQ: EIGI ) +26% . C&am...

BROOKLYN, N.Y., June 07, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), today announced that both the United States Patent and Trademark Office and the Japan Patent Office have respectively issued US Patent 10,118,92...

Enrollment in AzurRx’s Phase II OPTION study has reached target of 30-35 patients Screening activities have been completed in AzurRx’s Phase II Option study Top-line data expected in Summer 2019 NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NAS...

Thinly traded nano cap AzurRx BioPharma ( AZRX -9.3% ) is down on about 50% higher volume, albeit on turnover of only 153K shares, following its announcement of new data on candidate MS1819 SD in patients with chronic pancreatitis. Shares reversed shortly after the press release hit the ...

Statistical significance achieved on multiple secondary endpoints New data underscore the potential of MS1819 to provide meaningful clinical benefits to patients suffering from exocrine pancreatic insufficiency (EPI) NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (N...

Enrollment in AzurRx’s Phase II OPTION study passes 50% enrollment target Initial top line data of MS1819-SD in Cystic Fibrosis Patients expected in Summer 2019 NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company),...

AzurRx materially expands global commercial rights, with full development control of MS1819 program Mayoly retains certain commercial rights, while obtaining a sizeable equity interest in AzurRx BioPharma, Inc. (AZRX) shares. BROOKLYN, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- AzurR...

The following slide deck was published by AzurRx BioPharma, Inc. in conjunction with this Read more ...